Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 3 December 2004:
Vol. 306. no. 5702, pp. 1673 - 1675
DOI: 10.1126/science.306.5702.1673
Prev | Table of Contents | Next

News Focus

CLINICAL TRIALS:
Nail-Biting Time for Trials of COX-2 Drugs

Jennifer Couzin

Preliminary studies suggest that the COX-2 inhibitor Celebrex may stem cancer and Alzheimer's disease, but testing these possibilities has just gotten tougher.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Cardiovascular Effects of the Cyclooxygenase Inhibitors.
W. B. White (2007)
Hypertension 49, 408-418
   Full Text »    PDF »
The Promise of Prostaglandins: Have They Fulfilled Their Potential as Therapeutic Targets for the Delay of Preterm Birth?.
D. M. Olson (2005)
Reproductive Sciences 12, 466-478
   Abstract »    PDF »
Cyclooxygenase-2-derived Prostaglandin E2 Promotes Human Cholangiocarcinoma Cell Growth and Invasion through EP1 Receptor-mediated Activation of the Epidermal Growth Factor Receptor and Akt.
C. Han and T. Wu (2005)
J. Biol. Chem. 280, 24053-24063
   Abstract »    Full Text »    PDF »
The Prostaglandin E2 Receptor EP2 Is Required for Cyclooxygenase 2-Mediated Mammary Hyperplasia.
S.-H. Chang, Y. Ai, R. M. Breyer, T. F. Lane, and T. Hla (2005)
Cancer Res. 65, 4496-4499
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)